Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
AstraZeneca
Biotech
Takeda drops AZ-partnered neurological program after ph. 2 fail
Takeda has given up on an AstraZeneca-partnered neurological disorder program after the therapy flunked a phase 2 study.
James Waldron
Oct 30, 2025 9:25am
ESMO: The ADC 'rollercoaster' rides on with next-gen meds
Oct 21, 2025 3:00am
ESMO: AstraZeneca data 'validate' focus on in-house ADCs
Oct 18, 2025 12:55pm
AstraZeneca pens fresh IBD collab with Immunai worth $85M
Oct 16, 2025 9:00am
AstraZeneca: Building a transparent pipeline from the ground up
Oct 10, 2025 9:52am
Turbine looks to turbocharge AstraZeneca's ADC discovery
Oct 9, 2025 6:00am
